Mercado global de terapia com células estaminais alogénicas – Tendências do setor e previsão para 2030

 Análise e tamanho do mercado de terapia com células estaminais alogénicas

Os cientistas podem compreender melhor como as doenças e as perturbações se desenvolvem observando as células estaminais a transformarem-se em células dos ossos, do sistema cardiovascular, das terminações nervosas e de outros órgãos e tecidos. As células estaminais podem ser cultivadas em novos tecidos para transplante e engenharia genética. Os investigadores continuam a aprender mais sobre as células estaminais e as suas aplicações na medicina regenerativa, o que impulsionará o crescimento do mercado durante o período de previsão de 2023-2030.

A Data Bridge Market Research analisa que o mercado da terapia com células estaminais alogénicas, que foi de 994,9 milhões de dólares em 2022, deverá atingir os 2.109,50 milhões de dólares até 2030, com um CAGR de 9,85% durante o período de previsão de 2023 a 2030. Além dos insights em cenários de mercado como o valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia de doentes, análise de pipeline, análise de preços e enquadramento regulamentar.

Âmbito e segmentação do mercado de terapia com células estaminais alogénicas

Market Definition

Stem cell therapy, also known as regenerative medicine, uses stem cells or their derivatives to promote the repair response of dysfunctional,diseased, or injured tissue. Stem cells can develop into various types of cells in the body. Pluripotent and multipotent stem cells are the two main types of stem cells. Pluripotent stem cells are replicating cells that develop from embryonic or fetal tissues. Pluripotent stem cells help the cells and tissues develop in three primary germ layers: mesoderm, ectoderm, and endoderm.

Global Allogenic Stem Cell Therapy Market Dynamics

Drivers

• Increasing funding for stem cell research projects

The need for newer and better therapies for auto-immune, neurobiological, and coronary heart disease treatment has increased cumulative research activities and funding for cell-based research. For instance, the University of Sydney was awarded $6.3 million in June 2021 for three projects addressing adult vision loss and cardiovascular events and improving decisions about access to stem cell interventions. In the same year, Stanford physician-researchers were awarded nearly $31 million by the California Institute for Regenerative Medicine to begin first-in-human trials of stem therapies for treating stroke, heart failure, and a type of brain and spinal cord tumor. These are certain factors that propel the growth of the market.

• Rising number of launches

Increased product launches by key market players are expected to drive the market during the forecast period. For instance, LifeCell, a healthcare service provider, introduced an advanced umbilical cord-stem cell collection kit in August 2017 that protects neonatal stem cells from environmental damage and temperature fluctuations.

Opportunities

• Potential of stem cells for drug discovery

The ability to continuously develop functioning adult tissues in culture using directed differentiation opens up new avenues for drug discovery. Before conducting in vivo trials, researchers can create distinct cell lines and then test novel medications on each cell type in vitro to identify potential interactions. This is critical in developing medicines for use in veterinary research because of the possibility of species-specific combinations. The goal is to having the cell lines available for research use that will reduce the need for research animals because in vitro effects on human tissue will provide insight not previously known before the animal testing phase. These all are the factors which are expected to boost the market growth.

Restraints/Challenges

• Limited awareness regarding treatment

The main factors impeding the growth of the global allogenic stem cell therapy market are a lack of awareness about treatment options and ethical concerns about embryonic stem cells. For instance, according to data published by the National Center for Biotechnology Information, the main factor is the population's fear of unknown therapies and lack of awareness about treatment options. Furthermore, the high cost of the therapies leads to lower adoption, resulting in lower demand for the product globally.

This allogenic stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the allogenic stem cell therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Allogenic Stem Cell Therapy Market

The COVID-19 pandemic had a negative impact on the global allogenic stem cell therapy market due to a decrease in stem cell therapy research and development. The COVID-19 pandemic has caused significant disruption in research, manufacturing, and clinical development, according to the National Center for Biotechnology Information. Clinical trial disruption will erode the quality of clinical evidence for CGTs further, making a reliable HTA on the treatment benefits and economic impacts of CGTs even more difficult.

Furthermore, the current situation of COVID-19 is driving the growth of the market, as research activities for COVID-19 treatment are proceeding. Stem cell therapy may also be a promising treatment option for COVID-19 in the future. For instance, Lineage Cell Therapeutics, received a USD 5 million grant from the California Institute for Regenerative Medicine (CIRM) on May 6, 2020, to support the use of VAC, Lineage's allogeneic dendritic cell therapy, in the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

Recent developments

• In December 2021, Century Therapeutics, a biotechnology company, collaborated with Bristol Myers Squibb, a pharmaceutical company, and signed a licence agreement to develop and commercialise up to four induced pluripotent stem cell ("iPSC") derived, engineered natural killer cell ("iNK") and T cell ("iT") programmes for hematologic malignancies and solid tumors.

Global Allogenic Stem Cell Therapy Market Scope

The allogenic stem cell therapy market is segmented on the basis of product type, cell source, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Adult Stem Cells
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells

 Cell Source

• Adipose Tissue-Derived Mesenchymal Stem Cells
• Bone Marrow-Derived Mesenchymal Stem Cells
• Cord Blood/Embryonic Stem Cells
• Others

 Applications

• Musculoskeletal Disorders
• Wounds
• Injuries
• Cardiovascular Diseases
• Surgeries
• Gastrointestinal Diseases
• Other

 End Users

• Therapeutic Companies
• Cell and Tissues Banks
• Tools and Reagent Companies
• Service Companies

Allogenic Stem Cell Therapy Market Regional Analysis/Insights

The allogenic stem cell therapy market is analysed and market size insights and trends are provided by country, product type, cell source, application and end users as referenced above.

The countries covered in the allogenic stem cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the allogenic stem cell therapy market due to the improved investment scenario, technological advancements, and high economic growth.

Asia-Pacific is expected to grow at the highest growth rate from 2023 to 2030, owing to the surge in the prevalence of target chronic diseases.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Base instalada de crescimento da infraestrutura de saúde e penetração de novas tecnologias

O mercado de terapia com células estaminais alogénicas também fornece análises de mercado detalhadas para o crescimento de cada país em despesas de saúde para equipamentos de capital, base instalada de diferentes tipos de produtos para o mercado de terapia com células estaminais alogénicas, impacto da tecnologia utilizando curvas de linha de vida e mudanças na regulamentação da saúde. Os dados estão disponíveis para o período histórico 2011-2021.

Análise do cenário competitivo e da quota de mercado da terapia com células estaminais alogénicas

O panorama competitivo do mercado de terapia com células estaminais alogénicas fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado da terapia com células estaminais alogénicas.

Alguns dos principais players que operam no mercado da terapia com células estaminais alogénicas são:

• • (EUA)
• • Mesoblast Ltd (Austrália)
• • (EUA)
• • Pluristem, Lda.
• • Brainstorm Cell Limited. (NÓS)
• • (EUA)
• • Célula Gamida (EUA)
• • HOPE BIOSCIENCES (EUA)
• • Grupo de Biomedicina Celular (EUA)
• • Smith + Sobrinho (Reino Unido)
• • MEDIPOST (Coreia do Sul)
• • ANTEROGEN.CO, LDA. (Coreia do Sul)
• • (EUA)
• • RTI Cirúrgica (EUA)
• • AlloSource (EUA)
• • (Japão)
• • Takeda Pharmaceutical Company Limited (Japão) 

SKU-56872